Does Rallies show 13F holders for NRIX?

Yes. Rallies tracks hedge fund and 13F ownership data for NRIX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is NRIX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NRIX. It does not provide personalized investment advice.

NRIX (Nurix Therapeutics, Inc. Common stock) Stock Analysis - Hedge Fund Holdings

Nurix Therapeutics, Inc. Common stock (NRIX) is a publicly traded Healthcare sector company. As of May 20, 2026, NRIX trades at $16.03 with a market cap of $1.60B and a P/E ratio of -5.12. NRIX moved +8.01% today. Year to date, NRIX is -6.12%; over the trailing twelve months it is +61.93%. Its 52-week range spans $8.18 to $29.56. Analyst consensus is strong buy with an average price target of $30.43. Rallies surfaces NRIX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns NRIX stock?

Hedge funds tracked by Rallies that own NRIX include Redmile Group and Duquesne Family. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Nurix Therapeutics, Inc. Common stock.

NRIX Key Metrics

Key financial metrics for NRIX
Metric	Value
Price	$16.03
Market Cap	$1.60B
P/E Ratio	-5.12
EPS	$-3.17
Dividend Yield	0.00%
52-Week High	$29.56
52-Week Low	$8.18
Volume	1.50M
Avg Volume	0
Revenue (TTM)	$71.78M
Net Income	$-295.28M
Gross Margin	0.00%

Top Hedge Funds Holding NRIX

Redmile Group holds 7.73M shares of NRIX, changed -4.46% as of Mar 31, 2026.
Duquesne Family holds 44.20K shares of NRIX, changed +0.00% as of Sep 30, 2024.

Latest NRIX News

Nurix Presents 142% BRAF PDX Survival Gain and 60% SCLC Model Response — Apr 22, 2026
Nurix Therapeutics Faces 85.8% Upside with $30.18 Mean Price Target — Apr 11, 2026
Nurix Advances Phase 3 CLL Trial, Posts $6.3M Q1 Revenue and $540.7M Cash — Apr 8, 2026
Nurix to Showcase CBL-B, AURKA and BRAF Degraders at AACR 2026 — Mar 23, 2026
Nurix Sees STAT6 IND Filing, BTK Phase 1 Data and Superior IRAK4 Skin Penetration — Feb 14, 2026

Recent NRIX Insider Trades

van Houte Hans sold 13.47K (~$223.32K) on May 5, 2026.
van Houte Hans sold 582 (~$10.00K) on May 5, 2026.
Ring Christine sold 8.15K (~$138.21K) on May 4, 2026.

NRIX Analyst Consensus

8 analysts cover NRIX: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.43.

Common questions about NRIX

Who owns NRIX stock?: Hedge funds tracked by Rallies that own NRIX include Redmile Group and Duquesne Family. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Nurix Therapeutics, Inc. Common stock.
Does Rallies show 13F holders for NRIX?: Yes. Rallies tracks hedge fund and 13F ownership data for NRIX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is NRIX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NRIX. It does not provide personalized investment advice.